| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections | Frank Vinluan | 08/12/20 | Europe |
| Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political | Derrick Gingery | 08/12/20 | National |
| Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup | Sarah de Crescenzo | 08/11/20 | San Diego |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
| Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials | Sarah de Crescenzo | 08/11/20 | National |
| Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3 | Frank Vinluan | 08/10/20 | Boston |
| FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy | Sarah de Crescenzo | 08/07/20 | National |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare | Sarah Karlin-Smith | 08/07/20 | National |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| G1 Vets Launch Arc Therapeutics to Take on New Cancer Target | Sarah de Crescenzo | 08/06/20 | Raleigh Durham |
| Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds | Frank Vinluan | 08/06/20 | San Francisco |
| IgGenix Grabs $10M to Advance Antibody Treatments for Allergies | Sarah de Crescenzo | 08/05/20 | San Francisco |
| As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up | Frank Vinluan | 08/05/20 | New York |
| GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology | Frank Vinluan | 08/05/20 | Boston |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
| CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage | Sarah de Crescenzo | 08/04/20 | San Francisco |
| AbbVie Walks From Voyager R&D Pact Spanning Alzheimer’s, Parkinson’s | Frank Vinluan | 08/04/20 | Boston |
| MorphoSys, Incyte Get Early FDA Nod for Antibody Alternative to CAR-T | Frank Vinluan | 08/03/20 | Europe |
| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D | Sarah de Crescenzo | 07/30/20 | San Francisco |
| AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients | Frank Vinluan | 07/30/20 | Boston |
| Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort | Sarah de Crescenzo | 07/29/20 | San Diego |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| 2020 National Xconomy Awards Finalists Announced | Editors | 07/29/20 | National |
| Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology | Frank Vinluan | 07/29/20 | Boston |
